Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data

This article has been corrected. Please see J Manag Care Spec Pharm, 2020;26(10):1256 BACKGROUND: Targeted immunomodulators (TIMs) are used for the treatment of moderate to severe rheumatoid arthritis (RA) and include biologic and nonbiologic medications with different mechanisms of action. Data des...

Descripción completa

Detalles Bibliográficos
Autores principales: Gharaibeh, Mahdi, Bonafede, Machaon, McMorrow, Donna, Hernandez, Ervant J. Maksabedian, Stolshek, Bradley S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398701/
https://www.ncbi.nlm.nih.gov/pubmed/32715967
http://dx.doi.org/10.18553/jmcp.2020.26.8.1039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398701/
https://www.ncbi.nlm.nih.gov/pubmed/32715967
http://dx.doi.org/10.18553/jmcp.2020.26.8.1039

Ejemplares similares